Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to -$85.2 million.

  • Northwest Biotherapeutics' Net Income towards Common Stockholders fell 39.35% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.2 million, marking a year-over-year decrease of 28.46%. This contributed to the annual value of -$85.2 million for FY2024, which is 32.34% down from last year.
  • As of FY2024, Northwest Biotherapeutics' Net Income towards Common Stockholders stood at -$85.2 million, which was down 32.34% from -$64.4 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Net Income towards Common Stockholders ranged from a high of $179.1 million in FY2021 and a low of -$529.8 million during FY2020.
  • In the last 3 years, Northwest Biotherapeutics' Net Income towards Common Stockholders had a median value of -$85.2 million in 2024 and averaged -$84.9 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' Net Income towards Common Stockholders plummeted by 2,445.75% in 2020 and then surged by 133.81% in 2021.
  • Northwest Biotherapeutics' Net Income towards Common Stockholders (Yearly) stood at -$529.8 million in 2020, then spiked by 133.81% to $179.1 million in 2021, then tumbled by 158.64% to -$105.0 million in 2022, then skyrocketed by 38.71% to -$64.4 million in 2023, then tumbled by 32.34% to -$85.2 million in 2024.